Lead Product(s): Conestat Alfa
Therapeutic Area: Genetic Disease Product Name: Ruconest
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: NewBridge Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 20, 2021
Under the terms of the agreement, NewBridge will work closely with Pharming to provide access for RUCONEST® for the treatment of acute hereditary angioedema (“HAE”) in MENA.